The Drug Information Association's 2026 Global Annual Meeting brings together regulators from four continents, 20 of the world's leading pharmaceutical companies, and more than 4,100 drug development professionals to navigate the implications of AI-powered compound screening, clinical trial optimization, and personalized medicine. The event, scheduled for June 14-18 at the Pennsylvania Convention Center, will focus on harmonizing regulatory frameworks for AI-assisted drug development.
Overview
The meeting will feature over 150 sessions, including daily plenaries and keynote speakers. Physician-scientist and Every Cure co-founder David Fajgenbaum will deliver the opening keynote, while former White House public health official Rahul Gupta and former FDA Commissioner Robert Califf will also present.
What it Does
The meeting aims to address the biggest questions facing the field, including AI governance, GLP-1 innovation, CAR-T access, and global regulatory harmonization. The event will provide a platform for regulators, industry leaders, and professionals to come together and discuss the implications of AI in drug development.
Tradeoffs
The meeting highlights the need for harmonized regulatory frameworks to govern AI-assisted drug development. As AI moves faster than the frameworks designed to govern it, the industry is facing uncertainty and challenges in navigating the implications of AI-powered compound screening, clinical trial optimization, and personalized medicine.
When to Use It
The meeting is relevant to anyone involved in drug development, including regulators, industry leaders, and professionals. It provides a unique opportunity for collaboration and knowledge-sharing, and will help to address the biggest questions facing the field.
Bottom Line
The Drug Information Association's 2026 Global Annual Meeting is a critical event for the industry, bringing together key stakeholders to discuss the implications of AI in drug development. By harmonizing regulatory frameworks, the industry can ensure that AI-assisted drug development is safe, effective, and beneficial to patients.
The meeting will close on Thursday with a closing session featuring leaders from Google, OpenAI, Eli Lilly, Bain & Company, and Children's Hospital of Philadelphia. Standard registration rates end May 14, and hotels and full program details can be found at diaglobal.org/dia-2026. Media members can email [email protected] for credentials.
The Drug Information Association is a leading global non-profit life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.
Practical takeaway: The Drug Information Association's 2026 Global Annual Meeting is a must-attend event for anyone involved in drug development. By attending, professionals can stay up-to-date with the latest developments in AI-assisted drug development and network with key stakeholders in the industry.
Tags: [tag1, tag2, tag3] Sources used: Drug Information Association